Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results